i 1

PCNA-I1 is an inhibitor targeting PCNA chromatin association in prostate cancer.

O4I1 is an effective Oct3/4 inducer.

USP30-I-1, a selective inhibitor of USP30, exhibits an IC50 of 94 nM. This compound is utilized in research into diseases characterized by impaired mitochondrial autophagy, specifically targeting USP30.

AKT-I-1 is a selective and reversible inhibitor of Akt1.

Phox-I1 is a NOX2 inhibitor targeting the interactive site of p67phox with Rac GTPase.

HMS-I1 Hydrobromide is a probe that works by destroying heterochromatin mediated transcriptional gene silencing and is used for studies of heterochromatin formation and function.

6α-Prostaglandin I1 (6α-PGI1) is a stable Prostaglandin I2 (PGI2) analog resistant to hydrolysis in aqueous solutions. It promotes cyclic AMP accumulation in human thyroid slices and cells in a concentration-dependent manner but is about 10-fold less potent than the β-isomer and 100-fold less potent than PGI2 in eliciting this response. 6α-PGI1 exhibits an IC50 of 350 ng/ml for inhibition of ADP-induced platelet aggregation, nearly 900-fold higher than that of PGI2 (0.4 ng/ml).

Rilmenidine Phosphate is a selective I(1) imidazoline receptor agonist, used to treat hypertension.

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

Angiotensin I/II (1-6) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS) that contains the amino acids 1-6 and is converted from Angiotensin I/II peptide.

BH3I-1 (BHI1) is a Bcl-2 antagonist.

IL4I1-IN-1 is a selective inhibitor of interleukin 4 induced protein 1 (IL4I1). It suppresses the IL4I1-mediated oxidation and deamination of phenylalanine, thereby reducing the production of phenylpyruvate, H2O2, and NH3. This compound holds potential for research into cancers with high IL4I1 expression, such as endometrial cancer, ovarian cancer, and triple-negative breast cancer.

Rilmenidine hemifumarate (S-3341 hemifumarate) is a novel, orally active and selective I1 imidazoline receptor and α2-adrenoceptor agonist that induces autophagy, regulates the proliferation of leukaemia cells, stimulates the pro-apoptotic protein Bax, and induces autophagy in human leukaemia K5 cells. induces disruption of the mitochondrial pathway and apoptosis in human leukaemia K562 cells.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

6β-PGI1 is a stable PGI2 analog resistant to hydrolysis in aqueous solutions. 6β-PGI1 has a much longer half-life than PGI2, but a greatly reduced molar potency for receptor mediated function. 6β-PGI1 has a Kact for adenylate cyclase in NCB-20 cells of 4.2 μM compared with 18 nM for PGI2. The potency for vasodilation and inhibition of platelet aggregation is about 1% of PGI2.

M2I-1 a small Mad2 inhibitor-1. the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential proteinprotein interaction (PPI) within the SAC. It can disturbs conformational dynamics of Mad2 critical for complex formation with Cd

AZ-PRMT5i-1 (Compound 28) is an effective, orally-active MTAP-selective PRMT5 inhibitor. It exhibits synergistic properties with MTA and demonstrates anti-tumor activity both in vivo and in vitro, making it suitable for research in cancers lacking MTAP.

1-Hydroxybaccatin I possesses significant antinociceptive activity against p- benzoquinone-induced abdominal contractions.

Mogroside I A1, a triterpenoid glycoside isolated from extracts of Luo Han Guo, exhibits antioxidant, antidiabetic, and anticancer activities.

Mogroside I E1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, acts as a nonsugar sweetener.

1-Hydroxylbaccatin I is a useful organic compound for research related to life sciences and the catalog number is T131467.

AChE/CA I-IN-1 (Compound 2g) acts as an inhibitor for both AChE and hCA I, with Ki values of 1.85 µM and 0.53 µM, respectively. It has shown potential applications in the research of Alzheimer's disease, glaucoma, and epilepsy.

AChE/hCA I-IN-1 (Compound L3) is an inhibitor of acetylcholinesterase (AChE) and carbonic anhydrase (CA), effectively inhibiting AChE, hCA I, and hCA II with IC50 values of 302 nM, 265 nM, and 283 nM, respectively.

Topo I/II-IN-1 (compound 7t) is an effective dual inhibitor of Topo I and Topo II. It exhibits significant cytotoxicity against the MCF-7 breast cancer cell line, with an IC50 value of 7.45 μM.